RxDoctor Payments DataLook up a doctor →

Pablo Rengifo-Moreno, MD

Interventional Cardiology · Fort Lauderdale, FLNPI 1356500854

Payments from drug & device makers

$268,493in general payments, 2019–2025

Across 626 payments — averaging $428.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$188K
  • Abbott$26K
  • Edwards Lifesciences$19K
  • Medtronic$13K
  • Boston Scientific$13K
  • Abiomed$4K
  • plus $4K from 32 others
$278in research payments, 2019–2025

Across 3 payments — averaging $92.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$278

What the payments were for

  • Consulting fees$8,03013%
  • Speaking & faculty fees$5,0358%
  • Grants$5,3339%
  • Travel & lodging$16,91628%
  • Food & beverage$25,34642%
  • Education$1440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$268,493 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$219,879
Medicare patients
440
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$147,212
EntrestoSacubitril/Valsartan61$65,380
Repatha SureclickEvolocumab79$47,015
FarxigaDapagliflozin Propanediol29$31,116
JardianceEmpagliflozin44$28,060
BrilintaTicagrelor44$23,804
XareltoRivaroxaban12$11,935
Ranolazine ErRanolazine84$5,003
Metoprolol Succinate424$4,996
Atorvastatin Calcium277$3,614
VascepaIcosapent Ethyl11$2,082
Rosuvastatin Calcium157$1,385
Isosorbide Mononitrate ErIsosorbide Mononitrate171$1,282
Losartan Potassium152$1,272
Carvedilol126$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$147,212206 claims
NovartisEntresto$24$65,38061 claims
AstraZenecaFarxiga, Brilinta$97$54,92073 claims
Johnson & JohnsonXarelto$64$11,93512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →